ProMIS Neurosciences opened at $3.76, in line with its previous close of $3.76. In the last trading session, the stock traded between $3.40 and $3.84. It showed a downward intraday trend.
An investment of $100 made 5 years ago in ProMIS Neurosciences is now worth
$ 1.53
Resulting in a loss of
$ 98.47 (98.47%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.23 (-5.98%)
Day High
$3.84
Day Low
$3.40
Day Open
$3.76
Prev Close
$3.76
Volume
1,13,824
1W Return
2.76%
1M Return
-62.58%
3M Return
-76.10%
6M Return
-66.90%
1Y Return
-64.20%
Market Cap ($ Mn)
32
PE Ratio
-
PB Ratio
2.45
PEG Ratio
-
ROE
-592.72%
ROCE
-584.34%
EPS (TTM)
$-0.92
1 Week
2.76%
1 Month
-62.58%
3 Months
-76.10%
6 Months
-66.90%
9 Months
-75.80%
Roth Capital lowers ProMIS Neurosciences price target to $15, keeps Buy
Roth Capital lowered ProMIS Neurosciences' price target to $15. The previous price target was set at $29. The firm maintained a Buy rating on the stock. The price target reduction represents a $14 decrease.
10 days agoProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
Ivana Rubino, Ph.D., appointed Chief Commercial Officer effective October 5, 2026. Rubino brings 15+ years experience from Biogen and Roche in Alzheimer’s commercialization. Inducement grant includes 80,000 stock options at $9.37 exercise price. PMN310 Phase 1b topline data expected in Q1 2027.
1mo agoProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027
ProMIS Neurosciences reported Q2 2026 results with a net loss of $11.7 million and cash reserves of $53.4 million, extending its runway through 2027. The company highlighted zero ARIA-E cases in interim data for its Alzheimer's candidate PMN310, alongside early biomarker improvements.
3mo agoProMIS Neurosciences Q2 Results: Financial update scheduled for August 13, 2026
ProMIS Neurosciences Inc. has announced it will report its second quarter financial results for the period ended June 30, 2026, on August 13, 2026. An investor conference call and webcast will be hosted on the same day at 4:30 p.m. Eastern Time, with dial-in access available for both U.S. and international investors. The company, which focuses on antibody therapeutics and vaccines for neurodegenerative diseases, will also provide corporate updates during the event. A webcast replay will be accessible on the ProMIS website after the call concludes.
3mo agoProMIS Neurosciences PMN310 shows early Alzheimer's promise
ProMIS Neurosciences Inc announced positive interim results from its Phase 1b PRECISE-AD trial for PMN310, showing no ARIA-E cases and early tau biomarker declines in 136 patients. The data supports the drug's differentiated mechanism and safety profile, particularly for high-risk APOE4 carriers, sending shares up 18.67%.
3mo agoPMN310 shows dose-dependent reduction of amyloid-beta oligomers
ProMIS Neurosciences Inc. announced that its lead Alzheimer’s drug candidate, PMN310, demonstrated dose-dependent reduction of amyloid-beta oligomers in cerebrospinal fluid in a Phase 1a trial, presented at AAIC on July 14, 2026. The company is on track to present six-month blinded interim data from its ongoing PRECISE-AD Phase 1b trial in the coming weeks.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in ProMIS Neurosciences is now worth
$ 1.53
Resulting in a loss of
$ 98.47 (98.47%)
Note: Past profits do not guarantee future returns.
